---
schema_version: "secwatch.filing_event.v1"
accession: "0001728117-22-000057"
form_type: "8-K"
ticker: "GOSS"
cik: "0001728117"
company_name: "Gossamer Bio, Inc."
filed_at: "2022-07-13T23:59:59+00:00"
generated_at: "2026-06-24T16:01:37.601643+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Gossamer Bio raises $120M via private placement of 16.6M shares at $7.21/share

## Summary
- Private placement of 16.6M shares at $7.21; gross proceeds ~$120M before expenses.
- Participation by EcoR1 Capital, NEA, Weiss Asset Management, Rock Springs Capital, and others.
- Proceeds to fund seralutinib R&D ahead of Phase 2 TORREY topline results in Q4 2022.
- Expected close July 15, 2022; lock-up on shares until October 1, 2022.
- Cash runway extended into mid-2024 with existing cash and debt facility.

## SEC filing metadata
- accession: 0001728117-22-000057
- form_type: 8-K
- ticker: GOSS
- cik: 0001728117
- company_name: Gossamer Bio, Inc.
- filed_at: 2022-07-13T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000057/0001728117-22-000057-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1728117/000172811722000057/goss-20220713.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001728117-22-000057
- JSON: https://secwatch.observer/filing/0001728117-22-000057.json
- Plain text: https://secwatch.observer/filing/0001728117-22-000057.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.